Abstract

Case Report

Posterior Reversible Leukoencephalopathy Syndrome in a patient after second dose of Rituximab for treatment of resistant Thrombotic Thrombocytopenic Purpura

Sabaa Asif*, Sumbal Nasir Mahmood and Osama Kunwer Naveed

Published: 16 February, 2018 | Volume 2 - Issue 1 | Pages: 001-004

Posterior reversible encephalopathy syndrome (PRES) is a neurological syndrome with clinical features of altered sensorium, headaches, visual problems and seizures. It has been associated with uncontrolled hypertension (HTN), thrombotic thrombocytopenic purpura (TTP) and immunosuppressive drugs. Rituximab has also been implicated as a cause of PRES that usually occurs after the first dose. We report a case of PRES that occurred after the second dose of Rituximab. A twenty three years old female known case of resistant TTP treated with multiple courses of steroids and plasmapharesis was admitted with renal failure, severe volume overload ad lower respiratory tract infection. She was treated with hemodialysis, intravenous antibiotics, steroids and plasma exchange (PEX). 

Read Full Article HTML DOI: 10.29328/journal.jcn.1001010 Cite this Article Read Full Article PDF

References

  1. Mondal S, Goswami RP, Sinha D, Basu K, Das S, et al. Posterior reversible encephalopathy syndrome in a patient with lupus nephritis on rituximab therapy: a challenge to find the offender. Lupus. 2015; 25: 445-446. Ref.: https://goo.gl/AWWGxH
  2. Legriel S, Pico F, Azoulay E. Understanding Posterior Reversible Encephalopathy Syndrome. Annual Update in Intensive Care and Emergency Medicine. 2011; 1: 631-653. Ref.: https://goo.gl/JeGsDz
  3. Siddiqi A. Rituximab as a possible cause of posterior reversible encephalopathy syndrome. Australas Med J. 2011; 4: 513-515. Ref.: https://goo.gl/B3ZA8x
  4. Mehta Y, Ramachandran K, Gundre P, Kupfer Y, Tessler S. Posterior Reversible Encephalopathy Syndrome in a Patient with Newly Diagnosed Systemic Lupus Erythematosus and Thrombotic Thrombocytopenic Purpura. Chest. 2009; 136. Ref.: https://goo.gl/dLdrAA
  5. Harirchian M, Ghaffarpour M, Tabaeizadeh M, Siroos B. Immunosuppressive Drugs, an Emerging Cause of Posterior Reversible Encephalopathy Syndrome: Case Series. J Stroke Cerebrovasc Dis. 2015; 24:191-195. Ref.: https://goo.gl/Y2YLRj
  6. Mavragani CP, Vlachoyiannopoulos PG, Kosmas N, Boletis I, Tzioufas AG, et al. A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion. Rheumatology. 2004; 43: 1450-1451. Ref.: https://goo.gl/zqEeZX
  7. Vargas A, Zeidman LA. Posterior Reversible Encephalopathy Syndrome with Rituximab in Hodgkin’s Lymphoma and Idiopathic Thrombocytopenic Purpura. J Neurol Transl Neurosci. 2013; 1: 1023. Ref.: https://goo.gl/driFv1
  8. Bhat S, Rahman S. Rituximab Treatment in New and Refractory Thrombotic Thrombocytopenic Purpura (TTP) Patients: A Review. Int J Med Res Prof. 2016; 2: 1-6. Ref.: https://goo.gl/B9NbpY
  9. Scully M. Rituximab in the treatment of TTP. Hematology. 2012; 17: 22-24. Ref.: https://goo.gl/pQrHQa
  10. Habli M, Elyoussef N, Khoury M, Joubran Fares N. Rituximab-related posterior reversible encephalopathy syndrome in HUS patient post kidney transplant. Int J Case Rep Images. 2016; 7: 135-139. Ref.: https://goo.gl/b26waz

Figures:

Figure 1

Figure 1

Similar Articles

Recently Viewed

  • Non-invasive Serological Markers of Hepatic Fibrosis – Mini Review
    Elena Popa*, Raluca Ioana Avram, Andrei Emilian Popa and Adorata Elena Coman Elena Popa*, Raluca Ioana Avram, Andrei Emilian Popa, Adorata Elena Coman. Non-invasive Serological Markers of Hepatic Fibrosis – Mini Review. Arch Surg Clin Res. 2024: doi: 10.29328/journal.ascr.1001081; 8: 032-038
  • Imaging aspect of neuromyelitis optica: a case report and review of the literature
    H Lhajoui*, I Bounnit, N Moussali, A Merzem, O Amriss, H Belgadir and N Elbenna H Lhajoui*,I Bounnit,N Moussali,A Merzem,O Amriss,H Belgadir,N Elbenna. Imaging aspect of neuromyelitis optica: a case report and review of the literature. Arch Case Rep. 2021: doi: 10.29328/journal.acr.1001055; 5: 036-038
  • Renal denervation for resistant hypertension and heart failure with a reduced ejection fraction
    Carles Cañameras Fugasot, Oriol Rodríguez-Leor, Josep Riera Sadurní, Edgar Fadeuilhe, Javier Paul Martínez, Marina Urrutia Jou, Jordi Bover and Maribel Troya-Saborido* Carles Cañameras Fugasot,Oriol Rodríguez-Leor,Josep Riera Sadurní,Edgar Fadeuilhe,Javier Paul Martínez,Marina Urrutia Jou,Jordi Bover,Maribel Troya-Saborido*. Renal denervation for resistant hypertension and heart failure with a reduced ejection fraction. Ann Clin Hypertens. 2023: doi: 10.29328/journal.ach.1001033; 7: 001-003
  • Transformative Convergence: Exploring the Nexus of Engineering, Science and Technology in Intensive Care
    Ever Leonardo Rojas-Díaz* Ever Leonardo Rojas-Díaz*. Transformative Convergence: Exploring the Nexus of Engineering, Science and Technology in Intensive Care. Arch Case Rep. 2024: doi: 10.29328/journal.acr.1001095; 8: 056-057
  • A Rare Case of an Acquired Isolated Factor VII Deficiency was Discovered in a 23-Year-Old Female Patient
    Zahra Kmira*, Sassi Nedia, Ben Yahia Noura, Ben Sayed Nesrine, Greisha Ahmed, Mootameri Wided, Bouteraa Walid, Zaier Monia, Ben Youssef Yosra, Brahem Nejia, Haifa Regaieg and Khelif Abderrahim Zahra Kmira*, Sassi Nedia, Ben Yahia Noura, Ben Sayed Nesrine, Greisha Ahmed, Mootameri Wided, Bouteraa Walid, Zaier Monia, Ben Youssef Yosra, Brahem Nejia, Haifa Regaieg, Khelif Abderrahim. A Rare Case of an Acquired Isolated Factor VII Deficiency was Discovered in a 23-Year-Old Female Patient. J Hematol Clin Res. 2023: doi: 10.29328/journal.jhcr.1001025; 7: 025-028

Read More

Most Viewed

Read More

Help ?